Napo ends deal with Salix over lagging FDA filing for diarrhea drug
This article was originally published in Scrip
Executive Summary
Accusing Salix Pharmaceuticals of dragging its feet in seeking US approval for crofelemer, a first-in-class antisecretory agent extracted from the South American medicinal plant Croton lechleri, for HIV-associated diarrhea, despite positive Phase III data, Napo Pharmaceuticals said it was terminating its December 2008 deal with the firm.